Atara biotherapeutics presents preclinical data on ata3219, an allogeneic cd19-targeted car t therapy for the treatment of b-cell driven autoimmune diseases, at the isct 2024 annual meeting

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced preclinical data supporting the potential of ata3219, an allogeneic, anti-cd19 chimeric antigen receptor (car) t-cell therapy candidate for the treatment of b-cell driven autoimmune diseases. findings demon.
ATRA Ratings Summary
ATRA Quant Ranking